Navigation Links
TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
Date:9/22/2009

e safety measure of cardiac death or myocardial infarction (MI, commonly referred to as heart attack) remained numerically lower at three years for the TAXUS Liberte Atom Stent as compared to the TAXUS Express Atom Stent (6.5% vs. 7.4%, p=0.79).

"The TAXUS ATLAS Small Vessel Trial showed a sustained and significantly reduced risk of revascularization in small vessels for the TAXUS Liberte Atom Stent as compared to the TAXUS Express Atom Stent out to three years," said Mark A. Turco, M.D., Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, and Co-Principal Investigator of the trial. "Positive three-year data from the TAXUS ATLAS Long Lesion Trial showed the TAXUS Liberte Long Stent significantly reduces the risk of MI and cardiac death in long lesions compared to the TAXUS Express Stent, while reporting zero percent stent thrombosis. These data, combined with the previously reported reduction in nine-month late-loss, suggest that these improvements are likely the result of the thinner struts and improved stent geometry of the TAXUS Liberte Stent."

In the TAXUS ATLAS Long Lesion Trial, the TAXUS Liberte Long Stent demonstrated significantly improved safety outcomes when treating long lesions compared to the TAXUS Express Stent. The rate of cardiac death showed a significant 78 percent reduction in patients treated with the TAXUS Liberte Long Stent compared to the TAXUS Express Stent (1.5% vs. 6.7%, p=0.03). Overall MI showed a significant 72 percent reduction at three years in patients receiving a single TAXUS Liberte Long Stent compared to a single TAXUS Express Stent (2.9% vs. 10.4%, p=0.01). This improvement was primarily driven by a significant reduction in non-Q wave MI. The TAXUS Liberte Long Stent had zero stent thrombosis at three years using either the Protocol definition or the ARC definite/probable definition while the control TAXUS Express Stent reported 0.8 percent stent th
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Boston Scientific PROMUS(R) and First-Generation TAXUS(R) Express(R) Stents Continue Excellent Performance in SPIRIT III Trial
2. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
3. SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
4. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
5. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
6. TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
7. A consistent decline in heart attack rates following the implementation of smoking bans
8. Drug-eluting stents safe, effective for treatment of chronic total occlusions
9. Researchers find drug-eluting stents safe, effective for PCI in diabetics
10. New type of sirolimus-eluting stent demonstrates superior results
11. Sono-Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Motionsoft, Inc. announced today that it ... (PCI) Data Security Standards (DSS) certification, making it ... in the health and wellness space that has ... is the result of a collaborative effort formed ... International, MasterCard Worldwide, American Express, Discover Financial Services ...
(Date:12/17/2009)... PHILADELPHIA, Dec. 17 The recently opened ... already out in the community in full force this ... Run on December 13th, benefiting the Arthritis Foundation, a ... of arthritis. The event boasted 1,500 attendees, spotlighting LSI,s ... Run is a renowned, national fundraiser and a festive ...
(Date:12/17/2009)... and glutathione S-transferase T1 (GSTT1) null genotypes have been ... regarding the association between GSTM1 and GSTT1 null genotypes ... However, the majority of previous reports are limited by ... GSTM1/GSTT1 null genotype with the risk of GC and ... numbers of samples. , A research article to ...
(Date:12/17/2009)... DIEGO (December 17, 2009) Researchers from the ... aim at several of the world,s most dangerous infectious ... a five-year, $18.8 million federally-funded set of projects seeking ... , The Institute received four project awards ... and Infectious Diseases (NIAID), part of the National Institutes ...
(Date:12/17/2009)... one day provide therapeutic options for muscle and bone ... the umbilical cord, just as the blood that goes ... disorders, said University of Pittsburgh School of Medicine researchers ... Journal of Biomedicine and Biotechnology . , Umbilical ... are remarkably stable and might not trigger strong immune ...
Breaking Medicine News(10 mins):Health News:Motionsoft Completes PCI Compliance Certification 2Health News:Laser Spine Institute (LSI) Supports Jingle Bell Run 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 5Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2
... to the memory and scientific accomplishments of Dr. Judah ... and shed light on the link between blood supply ... (Volume 6, Number 3-4) of Lymphatic Research and ... the research impact of one of the pre-eminent physician-scientists ...
... a child born with cleft lip and palate often have ... a normal life. For some, this year,s resolution will ... philanthropy, members of the American Society of Plastic Surgeons (ASPS) ... give than to receive," by traveling overseas on behalf of ...
... Calif., Jan. 7 The surgical lights are on, ... West Coast,s most,advanced pediatric surgery center, at Lucile Packard ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090107/AQW023 ) , ... in December, provide the,latest in imaging and communication technologies, ...
... ZMH ; SWX: ZMH) announced today it will be ... on January 13, 2009,at 12:00 p.m. Eastern Time. , ... via Zimmer,s Investor,Relations website at http://investor.zimmer.com . The webcast ... About the Company , Founded in ...
... admission PHILADELPHIA, Jan. 7 /PRNewswire/ -- ... year,s Healthy Kids Fest on Sunday, January 11, 2009, at ... to 5 p.m. Just in time for those New Year,s ... and free activities for the whole family.The Blue Cross RiverRink ...
... L.P. today announced that it has settled a lawsuit brought ... in October 2005 pertaining to Medicaid reimbursements paid by the ... a full release of claims, Dey has agreed to pay ... 2007 acquisition agreement between Mylan Inc. (Dey,s parent company) and ...
Other Medicine News:Health News:Festschrift Issue honoring Judah Folkman, M.D., in Lymphatic Research and Biology 2Health News:New year brings new hope to children born with cleft lip, palate 2Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 2Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 3Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 4Health News:Families Encouraged to Enjoy Healthy Kids Fest at the Blue Cross RiverRink January 11 2Health News:Dey L.P. Settles State of Mississippi Pricing Litigation 2
(Date:12/17/2009)... Decision Resources, one of the world,s ... and healthcare issues, finds that over 70 percent ... high need for diabetes drugs with novel mechanisms ... is a high need for additional DPP-IV inhibitors. ... excellent glucose lowering ability and physicians in particular ...
(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... 2010 the U.S. Food and Drug Administration,s ... the New Drug Application (NDA) for pixantrone ... lymphoma (NHL). ODAC is an independent panel ... efficacy and safety of marketed and investigational ...
(Date:12/16/2009)... Ohio, Dec. 16 HDT Engineered Technologies ... generation technologies and a principal subcontractor for the ... led development of new anthropromorphic arm technology that ... prosthetic arm and hand, including a sense of ... Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics 2009 ...
Breaking Medicine Technology:Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Premiere Fibers Unveils New Logo Names for Innovative Brands 49074 1Premiere Fibers Unveils New Logo Names for Innovative Brands 49074 2Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 1Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 2Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 3Wyeth Announces Holder Right to Surrender Convertible Debentures 12653 4Torn Surgical Gloves Put Patients at Risk for Infection 49069 1Torn Surgical Gloves Put Patients at Risk for Infection 49069 2
... ... Treatment HUNTINGTON BEACH, Calif., and AMSTERDAM, ... cancer diagnostics,today announced the launch of TargetPrint(R), a new ... expression levels of,the estrogen receptor (ER), progesterone receptor (PR) ...
... and Education Foundation,s Within Our Reach Campaign Yields Significant ... ... 3 For the first time during its,unprecedented initiative to ... Research and Education Foundation is,releasing new information acquired from research ...
Other Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: